Our proprietary mAb generation platform encompasses immunogen design or using live-cell immunization (LC-I), high-efficient fusion (chemical), and live-cell high-throughput screening (LC-HTS), enabling the effective generation of functional mAbs that bind to novel or biologically functional targets and known antigens with high affinity and specificity. 

The in vivo-matured antibodies (hybridoma technology) typically exhibit nanomolar-range binding affinities and strong developability profiles. Combined with our specialized antibody engineering process (chimeric, humanization, maturation and production cell line generation, etc.), our antibody candidates can be seamlessly advanced into downstream production for preclinical and clinical development.